|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.12/-1.37
|
企業價值
30.11M
|
資產負債 |
每股賬面淨值
1.62
|
現金流量 |
現金流量率
--
|
損益表 |
收益
10.09M
|
每股收益
0.10
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/13 20:21 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |